Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

66.7%

2 terminated out of 3 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 1 (1)
P 2 (1)

Trial Status

Terminated2
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT05086315Phase 1TerminatedPrimary

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT06947044Not ApplicableRecruiting

Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding

NCT01440179Phase 2TerminatedPrimary

SAR3419 in Acute Lymphoblastic Leukemia

Showing all 3 trials

Research Network

Activity Timeline